Investors pump $130M into protein degrader startup GlycoEra

Kyle LaHucik

Biotech Correspondent

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B funding to get into the clinic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Investors pump $130M into protein degrader startup GlycoEra

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

The fate of Moderna’s next-gen Covid shot looms large after a flurry of policy changes

A new dawn for psychedelics? Compass could be the first to find out

Novo Nordisk ‘strongly’ urges against pharma tariffs as comments flood in

Weeks after TIGIT fail, iTeos decides to wind down

From weeks to days: how Aizon Intelligent Agents transform pharma validation

In­vestors pump $130M in­to pro­tein de­grad­er start­up Gly­co­Era

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Investors pump $130M into protein degrader startup GlycoEra